Our Blog Melanoma360

Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
06/05/2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Early data for imneskibart with aldesleukin presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)”
06/05/2026

Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)

Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago show that an mRNA individualized neoantigen…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Why Are Young People Tanning Again? What a New Allure Feature Reveals About Melanoma Prevention Challenges”
06/03/2026

Why Are Young People Tanning Again? What a New Allure Feature Reveals About Melanoma Prevention Challenges

A recent feature in Allure magazine explores a concerning trend: The resurgence of tanning culture among younger generations. The article…
Blog - Melanoma360
Featured image for “Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA”
05/29/2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies,…
Blog - Melanoma360
, 
Breaking News
Featured image for “The Importance of Self-Advocacy”
05/26/2026

The Importance of Self-Advocacy

by Mara Klecker Donna Altes was in her late 70s when she received her melanoma diagnosis, which came after a…
Blog - Melanoma360
, 
Survivor Stories
Featured image for “Webinar: Post-ASCO Melanoma Research Update”
05/21/2026

Webinar: Post-ASCO Melanoma Research Update

Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together leading cancer researchers and physicians from around…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Melanoma Monday: Every Day. Everywhere.”
05/04/2026

Melanoma Monday: Every Day. Everywhere.

May is Melanoma Awareness Month—but melanoma doesn’t follow a calendar. It doesn’t wait for summer vacations or long afternoons at…
Blog - Melanoma360
Featured image for “Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event”
04/27/2026

Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event

AIM at Melanoma is proud to partner once again with Lilly Pulitzer for their annual Community Giving Event. Now in…
Blog - Melanoma360
, 
Philanthropy
Featured image for “KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma”
04/19/2026

KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma

OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients”
04/10/2026

FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients

On April 10, 2026, the U.S. Food and Drug Administration (FDA) issued a decision not to approve the resubmission of…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
06/05/2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Early data for imneskibart with aldesleukin presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support…
Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
Blog - Melanoma360
 | 
Melanoma Research
06/05/2026

Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)

Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago show that an mRNA individualized neoantigen…
Featured image for “Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)”
Blog - Melanoma360
 | 
Melanoma Research
06/03/2026

Why Are Young People Tanning Again? What a New Allure Feature Reveals About Melanoma Prevention Challenges

A recent feature in Allure magazine explores a concerning trend: The resurgence of tanning culture among younger generations. The article…
Featured image for “Why Are Young People Tanning Again? What a New Allure Feature Reveals About Melanoma Prevention Challenges”
Blog - Melanoma360
05/29/2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies,…
Featured image for “Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA”
Blog - Melanoma360
 | 
Breaking News
05/26/2026

The Importance of Self-Advocacy

by Mara Klecker Donna Altes was in her late 70s when she received her melanoma diagnosis, which came after a…
Featured image for “The Importance of Self-Advocacy”
Blog - Melanoma360
 | 
Survivor Stories
05/21/2026

Webinar: Post-ASCO Melanoma Research Update

Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together leading cancer researchers and physicians from around…
Featured image for “Webinar: Post-ASCO Melanoma Research Update”
Blog - Melanoma360
 | 
Melanoma Research
05/04/2026

Melanoma Monday: Every Day. Everywhere.

May is Melanoma Awareness Month—but melanoma doesn’t follow a calendar. It doesn’t wait for summer vacations or long afternoons at…
Featured image for “Melanoma Monday: Every Day. Everywhere.”
Blog - Melanoma360
04/27/2026

Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event

AIM at Melanoma is proud to partner once again with Lilly Pulitzer for their annual Community Giving Event. Now in…
Featured image for “Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event”
Blog - Melanoma360
 | 
Philanthropy
04/19/2026

KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma

OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as…
Featured image for “KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
04/10/2026

FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients

On April 10, 2026, the U.S. Food and Drug Administration (FDA) issued a decision not to approve the resubmission of…
Featured image for “FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research

Recent Posts

Featured image for “Individualized Cancer Vaccine Shows Encouraging Results for Patients at High Risk for Recurrence”
Oct. 24, 2026

Individualized Cancer Vaccine Shows Encouraging Results for Patients at High Risk for Recurrence

Featured image for “Melanoma Treatment: What Happens When It’s Time for a Different Option?”
Sep. 30, 2026

Melanoma Treatment: What Happens When It’s Time for a Different Option?

Featured image for “Women in Melanoma: A New Chapter in Europe”
Aug. 31, 2026

Women in Melanoma: A New Chapter in Europe

Featured image for “The Legal & Financial Side of a Diagnosis: What No One Tells You”
Aug. 31, 2026

The Legal & Financial Side of a Diagnosis: What No One Tells You

Featured image for “Positive Phase 3 Results for Personalized mRNA Therapy in Melanoma”
Aug. 19, 2026

Positive Phase 3 Results for Personalized mRNA Therapy in Melanoma

Filter by Tag